CEO Martine Rothblatt于2026年3月16日出售了联合治疗公司的股份,因为尽管收入丰厚,股票略有下降。 CEO Martine Rothblatt sold shares in United Therapeutics on March 16, 2026, as stock dipped slightly despite strong earnings.

2026年3月16日, 联合治疗公司CEO Martine Rothblatt以534.99美元每人出售516股股票, On March 16, 2026, United Therapeutics CEO Martine Rothblatt sold 516 shares at $534.99 each, reducing her stake by 5.78% to 8,414 shares, valued at about $4.5 million. 该公司的股票关闭额为532.26美元,减少了3.86美元,交易额低于平均水平。 The company’s stock closed at $532.26, down $3.86, with below-average trading volume. 联合治疗公司报告了强的季度收益,每股收益7.70美元,超过估计的0.92美元,尽管收入7.902亿美元低于预期. United Therapeutics reported strong quarterly earnings, with $7.70 EPS, beating estimates by $0.92, though revenue of $790.2 million fell short of expectations. 该公司全年收入增长7.4%,净利润为41.94%,股本回报率为19.30%。 The company posted a 7.4% year-over-year revenue increase, a 41.94% net margin, and a 19.30% return on equity. 分析员预计,全年收益为每股24.48美元,股票的“多价购买”共识评级为548.09美元,目标价为548.9美元。 Analysts expect full-year earnings of $24.48 per share, and the stock holds a "Moderate Buy" consensus rating with a target price of $548.09.